Brokerages Set vTv Therapeutics Inc. (NASDAQ:VTVT) Price Target at $53.00

vTv Therapeutics Inc. (NASDAQ:VTVT) has received a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $53.00.

Several research analysts have recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of vTv Therapeutics in a research note on Monday, December 29th. Wall Street Zen upgraded vTv Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 14th. TD Cowen started coverage on vTv Therapeutics in a research report on Monday, January 5th. They set a “buy” rating on the stock. Roth Mkm assumed coverage on vTv Therapeutics in a research note on Thursday, January 22nd. They issued a “buy” rating and a $58.00 price objective on the stock. Finally, BTIG Research reaffirmed a “buy” rating and issued a $49.00 price objective on shares of vTv Therapeutics in a research report on Wednesday, March 11th.

vTv Therapeutics Trading Up 1.9%

NASDAQ:VTVT opened at $38.51 on Friday. The stock has a market capitalization of $151.73 million, a PE ratio of -11.50 and a beta of 0.44. vTv Therapeutics has a 1-year low of $14.00 and a 1-year high of $44.00. The firm has a fifty day simple moving average of $35.59 and a 200 day simple moving average of $30.80.

vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings results on Tuesday, March 10th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.09) by $0.51. The firm had revenue of ($0.02) million for the quarter.

Institutional Investors Weigh In On vTv Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Baker BROS. Advisors LP boosted its position in vTv Therapeutics by 52.4% during the third quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock worth $3,463,000 after purchasing an additional 51,000 shares during the period. Geode Capital Management LLC increased its holdings in shares of vTv Therapeutics by 84.3% in the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after purchasing an additional 12,896 shares during the last quarter. 683 Capital Management LLC acquired a new position in shares of vTv Therapeutics in the fourth quarter valued at $731,000. Finally, Goldman Sachs Group Inc. bought a new position in shares of vTv Therapeutics in the fourth quarter valued at about $221,000. Institutional investors and hedge funds own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.